Investigation of underlying comorbidities as risk factors for symptomatic human hepatitis E virus infection.
Investigation of underlying comorbidities as risk factors for symptomatic human hepatitis E virus infection.
复制标题
调查潜在的合并症作为有症状的人戊型肝炎病毒感染的危险因素。
DOI:
10.1111/apt.13938
复制
发表时间:
2017
期刊:
影响因子:
--
通讯作者:
Chen L
中科院分区:
文献类型:
--
作者:
Zhang S;Chen C;Peng J;Li X;Zhang D;Yan J;Zhang Y;Lu C;Xun J;Li W;Ling Y;Huang Y;Chen L
BackgroundSymptomatic Hepatitis E virus (HEV) infection occurs in few infected subjects, and the risk factors are not completely known.AimTo explore the risk factors for adverse clinical outcomes in acute HEV infections.MethodsA large retrospective study was conducted. The baseline characteristics, clinical outcomes, and laboratory data of 512 acute HEV infection cases were analysed using logistic regression models.ResultsAll patients exhibited autochthonous sporadic HEV infections, and most were elderly. Their symptoms varied from asymptomatic to severe liver diseases. In all, 215 patients (42.0%) had liver failure and/or decompensation, and 45 (8.2%) patients died within 3 months. Nearly 60% of patients had underlying chronic liver diseases (CLDs), 20% were cirrhotic, and various extrahepatic underlying comorbidities were common. The logistic regression analysis revealed that underlying CLDs, especially cirrhosis, were closely associated with disease severity (OR = 8.78,P< 0.001) but not with mortality in patients with severe liver diseases. In addition to the known factors, including an old age, the male gender and CLDs, we identified pre‐existing extrahepatic tumours, diabetes, and chronic respiratory and renal diseases as novel independent predictors for adverse clinical outcomes. Importantly, patients without these four extrahepatic comorbidities showed a much lower mortality rate (4.2%,P< 0.001) than patients with one (18.5%) or more comorbidities (34.5%).ConclusionsPrevious comorbidities, including tumours, diabetes, and chronic liver, lung and kidney diseases, were independent risk factors for adverse outcomes, especially mortality, in acute HEV infections. This study provides valuable data for improving the prevention and control of HEV infection.